ReviewBiotechnology advances2020
Vero cell upstream bioprocess development for the production of viral vectors and vaccines.
Review in Biotechnology advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Parameters Affecting Dengue Virus Replication in Vero Cells.Vaccine: X · 2026Article
- Highly efficient intranasal H5N1 vaccine based on a safe vesicular stomatitis virus (VSV) vector.Signal transduction and targeted therapy · 2026Article
- Cell assays in microcompartments driven by droplet microfluidics and hydrogel technologies.Journal of biochemistry · 2026Review
- Article
- DDIT3 Promotes Starvation-Induced Autophagy via ER Stress in Vero Cells.International journal of molecular sciences · 2026Article
- A continuous viral vaccine biomanufacturing platform utilizing multiple bioreactor configurations.Journal of biological engineering · 2026Article
- Poxvirus infection triggers remodeling of host m⁶A epitranscriptome and benefits from the m⁶A regulatory responses.Virology journal · 2026Article
- Accumulation of mutations in nsp4, E, and the S2 subunit underlies mammalian cell tropism expansion and virulence attenuation of avian coronavirus.PLoS pathogens · 2026Article
- Gammaretrovirus Infections in Humans in the Past, Present, and Future: Have We Defeated the Pathogen?Pathogens (Basel, Switzerland) · 2026Review
- Suspension cultivation of mosquito cell lines for the production of the mosquito-borne flavivirus Usutu virus in a stirred-tank bioreactor.Scientific reports · 2026Article
- Untargeted metabolomics reveals metabolic reprogramming and key metabolites in adherent and suspension Vero cells.Frontiers in cell and developmental biology · 2026Article
- CTGF knockdown in Vero cells reduces autophagy and adhesion and promotes short-term suspension adaptation.Frontiers in bioengineering and biotechnology · 2026Article
- Article
- Production of the Bakırköy strain of sheeppox vaccine virus in spinner flasks using an alternative method with Cytodex 1 microcarriers on Vero cells.BMC biotechnology · 2025Article
- In Vitro Evaluation of the Antiviral Effect ofViruses · 2025Article
- Viral vector-driven trans-encapsidation of replicon RNAs as a rapid approach for the development of safe and economically attractive anti-enterovirus vaccines.bioRxiv : the preprint server for biology · 2025Article
- Organoids in respiratory virus research: advances and perspectives.Molecular biomedicine · 2025Review
- Serum-Free Japanese Encephalitis Virus Production in a Single-Use Fixed-Bed Bioreactor.Engineering in life sciences · 2025Article
- Metavac-RSV mucosal bivalent vaccine candidate protects cotton rats against pneumoviruses and is produced using serum-free cell culture in bioreactor.NPJ vaccines · 2025Article
- ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses.Nature communications · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Vero cell line is considered the most used continuous cell line for the production of viral vectors and vaccines. Historically, it is the first cell line that was approved by the WHO for the production of human vaccines. Comprehensive experimental data on the production of many viruses using the Vero cell line can be found in the literature. However, the vast majority of these processes is relying on the microcarrier technology. While this system is established for the large-scale manufacturing of viral vaccine, it is still quite complex and labor intensive. Moreover, scale-up remains difficult and is limited by the surface area given by the carriers. To overcome these and other drawbacks and to establish more efficient manufacturing processes, it is a priority to further develop the Vero cell platform by applying novel bioprocess technologies. Especially in times like the current COVID-19 pandemic, advanced and scalable platform technologies could provide more efficient and cost-effective solutions to meet the global vaccine demand. Herein, we review the prevailing literature on Vero cell bioprocess development for the production of viral vectors and vaccines with the aim to assess the recent advances in bioprocess development. We critically underline the need for further research activities and describe bottlenecks to improve the Vero cell platform by taking advantage of recent developments in the cell culture engineering field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.